Company Overview and News

 
CIMB gets nod to form local JV with China Galaxy

2018-08-20 theedgemarkets
CIMB Group Holdings Bhd has obtained regulatory approval to proceed with the final piece of its two-part joint-venture partnership with China Galaxy Securities Co Ltd (CGS), a development that is expected to eventually provide it with some profit uplift and improve costs.
521105 1023 3018 BSMAF OLYMPTX 1818 CIMDF

 
CIMB gets Bank Negara nod, completes final piece for CIMB-China Galaxy stockbroking JV

2018-08-11 theedgemarkets
KUALA LUMPUR (Aug 10): CIMB Group Holdings Bhd has received Bank Negara Malaysia's (BNM) approval to incorporate a Malaysia-based joint venture (JV) company as the holding company of Jupiter Securities Sdn Bhd — the platform that will be used for the Malaysia stockbroking business of CIMB and China Galaxy Securities Co Ltd.
521105 1023 3018 OLYMPTX CIMDF

 
Dutaland receives U-Thant luxury apartments as settlement of debt

2018-06-14 theedgemarkets
KUALA LUMPUR (June 14): Dutaland Bhd said it will receive 12 vacant luxury residences worth RM45.4 million as part of a settlement of debt owed to its unit by listed firm Olympia Industries Bhd (OIB).
521105 3018 OLYMPTX

 
Olympia Industries

2018-04-04 thestar.com.my
OLYMPIA Industries Bhd made a move towards the 50-day simple moving average (SMA) at 12 sen on Tuesday, putting a halt to its staggered decline since January.
521105 3018 OLYMPTX

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...